

PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

NAME : Mr. MANGAT RAM

: 1687908 AGE/ GENDER : 38 YRS/MALE **PATIENT ID**

COLLECTED BY REG. NO./LAB NO. : 122412020011

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 09:47 AM BARCODE NO. **COLLECTION DATE** : 02/Dec/2024 09:58AM : 12505951 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 02/Dec/2024 11:54AM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Test Name Biological Reference interval**

CLINICAL CHEMISTRY/BIOCHEMISTRY

LIPID PROFILE: BASIC

CHOLESTEROL TOTAL: SERUM OPTIMAL: < 200.0 238.73^{H} mg/dL

by CHOLESTEROL OXIDASE PAP BORDERLINE HIGH: 200.0 -

239.0

HIGH CHOLESTEROL: > OR =

240.0

TRIGLYCERIDES: SERUM 473.29^H OPTIMAL: < 150.0 mg/dL by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC) BORDERLINE HIGH: 150.0 -

199.0

HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0

LOW HDL: < 30.0

HDL CHOLESTEROL (DIRECT): SERUM 36.45 mg/dL

by SELECTIVE INHIBITION BORDERLINE HIGH HDL: 30.0 -

60.0

 $HIGH\ HDL: > OR = 60.0$ LDL CHOLESTEROL: SERUM NOT CALCULATED OPTIMAL: < 100.0 mg/dL

by CALCULATED, SPECTROPHOTOMETRY ABOVE OPTIMAL: 100.0 - 129.0

BORDERLINE HIGH: 130.0 -

HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0

NON HDL CHOLESTEROL: SERUM 202.28^{H} mg/dL OPTIMAL: < 130.0 by CALCULATED, SPECTROPHOTOMETRY

ABOVE OPTIMAL: 130.0 - 159.0

BORDERLINE HIGH: 160.0 -

HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0

mg/dL VLDL CHOLESTEROL: SERUM NOT CALCULATED 0.00 - 45.00by CALCULATED. SPECTROPHOTOMETRY

TOTAL LIPIDS: SERUM NOT CALCULATED 350.00 - 700.00 mg/dL by CALCULATED, SPECTROPHOTOMETRY

CHOLESTEROL/HDL RATIO: SERUM 6.55^H RATIO LOW RISK: 3.30 - 4.40 by CALCULATED, SPECTROPHOTOMETRY

AVERAGE RISK: 4.50 - 7.0



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

NAME : Mr. MANGAT RAM

AGE/ GENDER : 38 YRS/MALE **PATIENT ID** : 1687908

COLLECTED BY REG. NO./LAB NO. : 122412020011

REFERRED BY **REGISTRATION DATE** : 02/Dec/2024 09:47 AM BARCODE NO. **COLLECTION DATE** : 02/Dec/2024 09:58AM : 12505951 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 02/Dec/2024 11:54AM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

| Test Name | Value | Unit | Biological Reference interval |
|---|--|-------|--|
| LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY | NOT CALCULATED | RATIO | MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 |
| | | | HIGH RISK: > 6.0 |
| TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY | 12.98 ^H | RATIO | 3.00 - 5.00 |
| NOTE 2 | WHEN TRIGLYCERIDES VALUE >400 mg/dL THE CALCULATED VALUES OF LDL AND VLDL ARE NOT RELIABLE | | |

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the

age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co-primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk

*** End Of Report ***



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)